-
Something wrong with this record ?
ADAM10 and ADAM17 regulate EGFR, c-Met and TNF RI signalling in liver regeneration and fibrosis
O. Zbodakova, K. Chalupsky, L. Sarnova, P. Kasparek, M. Jirouskova, M. Gregor, R. Sedlacek
Language English Country Great Britain
Document type Journal Article, Research Support, Non-U.S. Gov't
NLK
Directory of Open Access Journals
from 2011
Free Medical Journals
from 2011
Nature Open Access
from 2011-12-01
PubMed Central
from 2011
Europe PubMed Central
from 2011
ProQuest Central
from 2011-01-01
Open Access Digital Library
from 2011-01-01
Open Access Digital Library
from 2011-01-01
Health & Medicine (ProQuest)
from 2011-01-01
ROAD: Directory of Open Access Scholarly Resources
from 2011
Springer Nature OA/Free Journals
from 2011-12-01
- MeSH
- Fibrosis metabolism MeSH
- Liver * metabolism pathology MeSH
- Cells, Cultured MeSH
- Membrane Proteins physiology MeSH
- Mice, Inbred C57BL MeSH
- Mice MeSH
- Liver Diseases * metabolism pathology MeSH
- Primary Cell Culture MeSH
- ADAM10 Protein physiology MeSH
- ADAM17 Protein physiology MeSH
- Liver Regeneration * MeSH
- Amyloid Precursor Protein Secretases physiology MeSH
- Animals MeSH
- Check Tag
- Male MeSH
- Mice MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
ADAM10 and ADAM17 are proteases that affect multiple signalling pathways by releasing molecules from the cell surface. As their substrate specificities partially overlaps, we investigated their concurrent role in liver regeneration and fibrosis, using three liver-specific deficient mouse lines: ADAM10- and ADAM17-deficient lines, and a line deficient for both proteases. In the model of partial hepatectomy, double deficient mice exhibited decreased AKT phosphorylation, decreased release of EGFR activating factors and lower shedding of HGF receptor c-Met. Thus, simultaneous ablation of ADAM10 and ADAM17 resulted in inhibited EGFR signalling, while HGF/c-Met signalling pathway was enhanced. In contrast, antagonistic effects of ADAM10 and ADAM17 were observed in the model of chronic CCl4 intoxication. While ADAM10-deficient mice develop more severe fibrosis manifested by high ALT, AST, ALP and higher collagen deposition, combined deficiency of ADAM10 and ADAM17 surprisingly results in comparable degree of liver damage as in control littermates. Therefore, ADAM17 deficiency is not protective in fibrosis development per se, but can ameliorate the damaging effect of ADAM10 deficiency on liver fibrosis development. Furthermore, we show that while ablation of ADAM17 resulted in decreased shedding of TNF RI, ADAM10 deficiency leads to increased levels of soluble TNF RI in serum. In conclusion, hepatocyte-derived ADAM10 and ADAM17 are important regulators of growth receptor signalling and TNF RI release, and pathological roles of these proteases are dependent on the cellular context.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22004298
- 003
- CZ-PrNML
- 005
- 20220127145352.0
- 007
- ta
- 008
- 220113s2021 xxk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1038/s41598-021-90716-3 $2 doi
- 035 __
- $a (PubMed)34075077
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Zbodakova, Olga $u Laboratory of Transgenic Models of Diseases, Institute of Molecular Genetics of the Czech Academy of Sciences, Průmyslova 595, 252 50, Vestec, Czech Republic. olga.zbodakova@img.cas.cz
- 245 10
- $a ADAM10 and ADAM17 regulate EGFR, c-Met and TNF RI signalling in liver regeneration and fibrosis / $c O. Zbodakova, K. Chalupsky, L. Sarnova, P. Kasparek, M. Jirouskova, M. Gregor, R. Sedlacek
- 520 9_
- $a ADAM10 and ADAM17 are proteases that affect multiple signalling pathways by releasing molecules from the cell surface. As their substrate specificities partially overlaps, we investigated their concurrent role in liver regeneration and fibrosis, using three liver-specific deficient mouse lines: ADAM10- and ADAM17-deficient lines, and a line deficient for both proteases. In the model of partial hepatectomy, double deficient mice exhibited decreased AKT phosphorylation, decreased release of EGFR activating factors and lower shedding of HGF receptor c-Met. Thus, simultaneous ablation of ADAM10 and ADAM17 resulted in inhibited EGFR signalling, while HGF/c-Met signalling pathway was enhanced. In contrast, antagonistic effects of ADAM10 and ADAM17 were observed in the model of chronic CCl4 intoxication. While ADAM10-deficient mice develop more severe fibrosis manifested by high ALT, AST, ALP and higher collagen deposition, combined deficiency of ADAM10 and ADAM17 surprisingly results in comparable degree of liver damage as in control littermates. Therefore, ADAM17 deficiency is not protective in fibrosis development per se, but can ameliorate the damaging effect of ADAM10 deficiency on liver fibrosis development. Furthermore, we show that while ablation of ADAM17 resulted in decreased shedding of TNF RI, ADAM10 deficiency leads to increased levels of soluble TNF RI in serum. In conclusion, hepatocyte-derived ADAM10 and ADAM17 are important regulators of growth receptor signalling and TNF RI release, and pathological roles of these proteases are dependent on the cellular context.
- 650 _2
- $a protein ADAM10 $x fyziologie $7 D000072197
- 650 _2
- $a protein ADAM17 $x fyziologie $7 D000072198
- 650 _2
- $a sekretasy $x fyziologie $7 D053829
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a kultivované buňky $7 D002478
- 650 _2
- $a fibróza $x metabolismus $7 D005355
- 650 12
- $a játra $x metabolismus $x patologie $7 D008099
- 650 12
- $a nemoci jater $x metabolismus $x patologie $7 D008107
- 650 12
- $a regenerace jater $7 D008115
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a membránové proteiny $x fyziologie $7 D008565
- 650 _2
- $a myši $7 D051379
- 650 _2
- $a myši inbrední C57BL $7 D008810
- 650 _2
- $a primární buněčná kultura $7 D061251
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Chalupsky, Karel $u Laboratory of Transgenic Models of Diseases, Institute of Molecular Genetics of the Czech Academy of Sciences, Průmyslova 595, 252 50, Vestec, Czech Republic $u Czech Centre of Phenogenomics, Institute of Molecular Genetics of the Czech Academy of Sciences, Průmyslova 595, 252 50, Vestec, Czech Republic
- 700 1_
- $a Sarnova, Lenka $u Laboratory of Transgenic Models of Diseases, Institute of Molecular Genetics of the Czech Academy of Sciences, Průmyslova 595, 252 50, Vestec, Czech Republic $u Laboratory of Integrative Biology, Institute of Molecular Genetics of the Czech Academy of Sciences, Vídeňská 1083, 142 20, Prague, Czech Republic
- 700 1_
- $a Kasparek, Petr $u Laboratory of Transgenic Models of Diseases, Institute of Molecular Genetics of the Czech Academy of Sciences, Průmyslova 595, 252 50, Vestec, Czech Republic $u Czech Centre of Phenogenomics, Institute of Molecular Genetics of the Czech Academy of Sciences, Průmyslova 595, 252 50, Vestec, Czech Republic
- 700 1_
- $a Jirouskova, Marketa $u Laboratory of Transgenic Models of Diseases, Institute of Molecular Genetics of the Czech Academy of Sciences, Průmyslova 595, 252 50, Vestec, Czech Republic $u Laboratory of Integrative Biology, Institute of Molecular Genetics of the Czech Academy of Sciences, Vídeňská 1083, 142 20, Prague, Czech Republic
- 700 1_
- $a Gregor, Martin $u Laboratory of Transgenic Models of Diseases, Institute of Molecular Genetics of the Czech Academy of Sciences, Průmyslova 595, 252 50, Vestec, Czech Republic $u Laboratory of Integrative Biology, Institute of Molecular Genetics of the Czech Academy of Sciences, Vídeňská 1083, 142 20, Prague, Czech Republic
- 700 1_
- $a Sedlacek, Radislav $u Laboratory of Transgenic Models of Diseases, Institute of Molecular Genetics of the Czech Academy of Sciences, Průmyslova 595, 252 50, Vestec, Czech Republic. radislav.sedlacek@img.cas.cz $u Czech Centre of Phenogenomics, Institute of Molecular Genetics of the Czech Academy of Sciences, Průmyslova 595, 252 50, Vestec, Czech Republic. radislav.sedlacek@img.cas.cz
- 773 0_
- $w MED00182195 $t Scientific reports $x 2045-2322 $g Roč. 11, č. 1 (2021), s. 11414
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/34075077 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20220113 $b ABA008
- 991 __
- $a 20220127145349 $b ABA008
- 999 __
- $a ok $b bmc $g 1751690 $s 1155447
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2021 $b 11 $c 1 $d 11414 $e 20210601 $i 2045-2322 $m Scientific reports $n Sci Rep $x MED00182195
- LZP __
- $a Pubmed-20220113